Elevance Health Forecasts 2024 Operating Revenue Growth Of Flat To Low-Single Digits Over 2023 Sales Of $170.2B Versus Consensus Of $174.32B, With Adjusted EPS Of Greater Than $37.10 Versus Consensus Of $37.05
Portfolio Pulse from Benzinga Newsdesk
Elevance Health projects its 2024 operating revenue to grow from flat to low-single digits compared to 2023 sales of $170.2 billion, which is below the consensus estimate of $174.32 billion. The company also forecasts its adjusted EPS to be greater than $37.10, slightly above the consensus estimate of $37.05.
January 24, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Elevance Health forecasts a modest revenue growth for 2024, with expected sales below market consensus, but predicts a slightly higher adjusted EPS than the consensus estimate.
The projected revenue growth being below consensus may be viewed negatively by investors, potentially putting downward pressure on the stock. However, the higher forecasted adjusted EPS could offset some of the negative sentiment, as it suggests profitability may be better than expected. The mixed forecast creates uncertainty, leading to a neutral score.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100